99-30192. Nonclinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science; Notice of Meeting  

  • [Federal Register Volume 64, Number 223 (Friday, November 19, 1999)]
    [Notices]
    [Pages 63324-63325]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-30192]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Nonclinical Studies Subcommittee of the Advisory Committee for 
    Pharmaceutical Science; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). The meeting will 
    be open to the public.
        Name of Committee: Nonclinical Studies Subcommittee of the Advisory 
    Committee for Pharmaceutical Science
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA's regulatory issues.
        Date and Time: The meeting will be held on December 14, 1999, 8:30 
    a.m. to 5:30 p.m.
        Location: Holiday Inn, The Ballrooms, Two Montgomery Village Ave., 
    Gaithersburg, MD.
        Contact Person: Kimberly L. Topper at Tperk@cder.fda.gov or Angie 
    Whitacre at Whitacrea@cder.fda.gov, Center for Drug Evaluation and 
    Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, 
    Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee 
    Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
    area), code 12539. Please call the Information Line for up-to-date 
    information on this meeting.
        Agenda: The subcommittee will discuss collaborative approaches to 
    scientific research issues of common interest to the pharmaceutical 
    industry, universities, the public, and FDA. Specific areas of focus 
    will be in the nonclinical studies areas of: (1) Interspecies 
    biomarkers of toxicity, (2) high-resolution magnetic imaging, (3) 
    positron emission tomography imaging, and (4) methods to facilitate 
    early human assessments.
        Procedure: Interested persons may present data, information, or 
    views, orally or in writing, on issues pending before the committee. 
    Written submissions may be made to the contact person by December 9, 
    1999. Oral presentations from the public will be scheduled between 
    approximately 1 p.m. to 2 p.m. Time allotted for each presentation may 
    be limited. Those desiring to make formal oral presentations should 
    notify the contact person before December 9, 1999, and
    
    [[Page 63325]]
    
    submit a brief statement of the general nature of the evidence or 
    arguments they wish to present, the names and addresses of proposed 
    participants, and an indication of the approximate time requested to 
    make their presentation.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: November 10, 1999.
    Linda A. Suydam,
    Senior Associate Commissioner.
    [FR Doc. 99-30192 Filed 11-18-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
11/19/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-30192
Pages:
63324-63325 (2 pages)
PDF File:
99-30192.pdf